Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talfirastide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.73 |
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 6/20 | 0.55 |
| ▸ | NPY2R | P49146 | 5/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.55 |
| ▸ | NPY1R | P25929 | 4/20 | 0.55 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin-Ii SCHEMBL29362121 | 0.94 | AGTR2 (0.76) | AGTR2AGTR1NPY4RNPY2RNPY5R | |
| Angiotensin Ii SCHEMBL13232382 | 0.93 | AGTR2 (0.84) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL1189 | 0.93 | AGTR2 (0.84) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL2566771 | 0.93 | AGTR2 (0.84) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL14990505 | 0.93 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL3465991 | 0.93 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL21267957 | 0.93 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL2183118 | 0.92 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL1585377 | 0.92 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN | |
| Angiotensin Ii SCHEMBL8898391 | 0.92 | AGTR2 (0.83) | AGTR2AGTR1ANPEPLNPEPREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | OSPEDALE PEDIATRICO BAMBINO GESU (IT) | 2026-03-05 | — | — | US | claimed |
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250221947-A1 | METHODS FOR TREATING A CORONAVIRUS INFECTION USING VALPROIC ACID AND DOCOSAHEXAENOIC ACID | UNIV TEXAS (US) | 2025-07-10 | — | — | US | claimed |
| US-20250213469-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. | 2025-07-03 | — | — | US | claimed |
| EP-4422622-B1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | OSPEDALE PEDIATRICO BAMBINO GESÙ (IT) | 2025-06-18 | — | — | EP | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| US-20250082716-A1 | REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-03-13 | — | — | US | claimed |
| US-20250027942-A1 | COVID-19 THERANOSTIC | Université Libre de Bruxelles (BE) | 2025-01-23 | — | — | US | claimed |
| EP-4493276-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. (TR) | 2025-01-22 | — | — | EP | claimed |
| EP-4482481-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | claimed |
| WO-2022233913-A1 | ANGIOTENSIN-(1-7) IN THE TREATMENT OF SARS-COV RELATED DISEASES | CU-PHARMACEUTICALS UG (DE) | 2022-11-10 | — | — | WO | claimed |
| WO-2022233914-A1 | PHARMACEUTICAL ANGIOTENSIN-(1-7) COMPOSITIONS IN THE TREATMENT OF (SARS)-COV- OR (SARS)-COV-2-INFECTION RELATED DISEASES | CU-PHARMACEUTICALS UG (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-4085896-A1 | PHARMACEUTICAL ANGIOTENSIN-(1-7) COMPOSITIONS IN THE TREATMENT OF (SARS)-COV- OR (SARS)-COV-2-INFECTION RELATED DISEASES | CU-Pharmaceuticals UG (DE) | 2022-11-09 | — | — | EP | claimed |
| EP-4085921-A1 | ANGIOTENSIN-(1-7) IN THE TREATMENT OF SARS-COV RELATED DISEASES | CU-Pharmaceuticals UG (DE) | 2022-11-09 | — | — | EP | claimed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | claimed |
| CN-109553658-B | Ang- (1-7) aza polypeptide analogue, preparation method and application | 重庆大学 | 2022-10-04 | — | — | CN | claimed |
| US-20220233659-A1 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-07-28 | — | — | US | claimed |
| WO-2022094025-A1 | ANGIOTENSIN-1-7 FOR THE TREATMENT OF COVID-19 | DIZEREGA GERE (US) | 2022-05-05 | — | — | WO | claimed |
| US-11241487-B2 | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | AGTR2 30/4885AGTR1 37/4885ANPEP 980/4885 |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | MTPN, UTRN, TTN | AGTR2 928/4885AGTR1 1133/4885ANPEP 28/4885 |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | BACE1, BACE2, PSENEN | AGTR2 3295/4885AGTR1 3149/4885ANPEP 97/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | AGTR2 76/4885AGTR1 51/4885ANPEP 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.